Eris Lifesciences is an Indian branded formulations company offering chronic disease management and specialized treatments to healthcare professionals.
Eris reports a **39% year-over-year profit increase** in Q2 FY27, driven by growth in its diabetes-related products and services. The company highlights strong demand for its solutions targeting diabetes management. Financial performance reflects sustained revenue momentum in its core health-tech segment.
Eris Lifesciences is acquiring its injectable unit, Swiss Parenterals, in a **Rs 423.3 crore share swap deal** to strengthen operational control and financial integration. The company also reports **higher Q2 revenue and profit**, signaling growth momentum. The move consolidates Eris’s manufacturing capabilities under a single entity.
Eris Lifesciences appoints Gopal Agrawal and Nita Borkar to leadership positions within its Domestic Branded Formulations business. The company specializes in branded pharmaceutical formulations in India. These appointments aim to strengthen its core operations in the domestic market.
Eris Lifesciences appoints Gopal Agrawal and Nita Borkar to leadership positions within its Domestic Branded Formulations division. The move strengthens operational oversight of the company’s branded pharmaceutical products. Both executives bring experience in formulation and business development to their new roles.
